<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 289 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page288.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=289">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 289 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 289</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=289"><img src="../thumb/289.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>252 / 2020-04                                                            Anti-Microbials - 18.10
   Contraindications: Concom. terfenadine with multiple fluconazole   Use in childr.4 wks.& young: In 1st 2 wks.of life: Use same mg/  Contraindications: Concom. terfenadine with multiple fluconazole
   dos.&gt;400 mg/day, concom. cisapride, pregn.(congenit.malformat.  kg dos.as for older childr.but admin.every 72 hrs. Wks. 3-4: Same   dos.&gt;400 mg/day, concom. cisapride, pregn.(congenit.malformat.
   report), lactat. (passes into breast milk), multiple dos.ther. in ren.im-  dos.but every 48 hrs.  report), lactat. (passes into breast milk), multiple dos.ther. in ren.im-
   pairm., avoid concom.astemizole.  Contraindications: Known sens.to relat.azole/ triazole cmpnds,   pairm., avoid concom.astemizole.
   Side effects: Hepat. ren.& haematolog.funct. disturbs.partic.in pts.  concom. terfenadine with multiple fluconazole dos. &gt;400 mg/day,   Side effects: Hepat. ren.& haematolog.funct. disturbs. partic.in pts.
   with ser.underly.dis.such as AIDS and Ca, skin rash & reacts., angi-  concom.meds. known to prolong QT interv./metabol.via CYP3A4   with ser.underly.dis.such as AIDS and Ca, skin rash & reacts., angi-
   oed., bld. dyscras., headache, CNS effs., hypokalaem., hypercholes-  incl.cisapride/ astemizole/ erythromycin/ pimozide/ quinidine,   oed., bld. dyscras., headache, CNS effs., hypokalaem., hypercholes-
   terolaem., hypertriglyceridaem., GI disturbs., fem.sex.dysfunct., inter-  pregn.& lactat., multiple dos. ther.in ren.impairm.  terolaem., hypertriglyceridaem., GI disturbs., fem.sex.dysfunct., inter-
   menst.bleed., menorrhag., leukorrh., polyruia, hepatotox., hyperton.,   Side effects: Alopec., exfoliat.skin disords.incl. Stev.Johns.syndr.&   menst.bleed., menorrhag., leukorrh., polyruia, hepatotox., hyperton.,
   abnorm.vis., alopec., allerg.reacts.incl. anaphylax., flush.  tox.epiderm.necrolys., headache, rash, prurit., urticar., sweat., drug   abnorm.vis., alopec., allerg.reacts.incl. anaphylax., flush.
   Special precautions: Discont.ther.when pts. with syst. fung.infects.  erupt., GI disturbs., hepat./ren.& haematolog.funct. disturbs.partic.  Special precautions: Discont.ther.when pts. with syst. fung.infects.
   develop.bullous les./ erythema multiforme, monit.pts.receiv.concom.   in pts.with ser. underly.dis., QT interv. prolongat./torsade de pointes.,   develop.bullous les./ erythema multiforme, monit.pts.receiv.concom.
   terfenadine at fluconazole dos.&lt;400 mg/day, imp.ren.funct., monit.  CNS effs., dizzin., seiz., trem., vertigo, leucopen., neutropen.,   terfenadine at fluconazole dos.&lt;400 mg/day, imp.ren.funct., monit.
   liv.funct.in contin.ther. long.than 1 mnth./when S&S of liv.dysfunct.   agranulocytos.,  thrombocytopen.,  anaphylax.,  hepat.fail./toxic.,   liv.funct.in contin.ther.long. than 1 mnth./ when S&S of liv.dysfunct.
   devel., underly.dis.e.g. AIDS/malign.  hepatit., hepatocellul.necros./ damage, jaund., cholestas., incr.  devel., underly.dis.e.g. AIDS/malign.
   Warnings:  Monit.pts.develop.abnorm.liv.funct. for more seri-  bilirub./alanine  aminotransfer./aspartate  aminotransfer./bld.  Warnings:  Monit.pts.develop.abnorm.liv.funct. for more seri-
   ous hepat.injur.             alkal. phosphat. hypercholesterolaem., hypertriglyceridaem.,   ous hepat.injur.
   Drug interactions: Incr.plasma conc.of meds. metabol. by cyto-  hypokalaem., thirst, polyur., insomn., nervousn., fem.sex.dysfunct.,   Drug interactions: Incr.plasma conc.of meds. metabol. by cyto-
   chrome P-450 system, prolongs prothromb.time in warfarin ther., pro-  intermenst. bleed., leukorrh., menorrhag., fatig., malaise, asthen.,   chrome P-450 system, prolongs prothromb.time in warfarin ther., pro-
   longs serum half-life of oral sulphonylureas, phenytoin/ zidovudine,/   fev., rigors, flush., taste pervers., abnorm. vis./odour  longs serum half-life of oral sulphonylureas, phenytoin/ zidovudine, /
   rifabutin & tacrolimus plasma conc. incr., theophyll.clear.reduc., ser.  Warnings and special precautions: AIDS pts. more suscept.to   rifabutin & tacrolimus plasma conc. incr., theophyll.clear.reduc., ser.
   life threaten.card. arrhythm.incl.torsades de pointes with cisapride,   cutan.reacts., monit.pts. receiv. concom.terfenadine at fluconazole   life threaten.card. arrhythm.incl.torsades de pointes with cisapride,
   cyclospor.ser.conc.incr., incr.midazolam & triazolam ser.conc.partic.  dos.&gt;400 mg/ day, imp.ren.funct., bleed.events report.with concom.   cyclospor.ser.conc.incr., incr.midazolam & triazolam ser.conc.partic.
   aft.oral fluconaz.admin., hydrochlorothiaz.incr.fluconazole plasma   warfar., incr.risk of theophyll.toxic., min. oral surg.& dent.proced., IV   aft.oral fluconaz.admin., hydrochlorothiaz.incr.fluconazole plasma
   conc., rifampicin decr.fluconazole plasma conc., nevirapine expos.  infus.in pts.requir. Na / fluid restsrict., uveit.in pts.receiv.rifabutin,   conc., rifampicin decr.fluconazole plasma conc., nevirapine expos.
                                          +
   incr.by approx.100%.         nephrotox. report.with tracrolimus, concom.meds. with a narr.  incr.by approx.100%.
   DAKTARIN, Janssen Pharmaceutica (Pty) Ltd.  therap.window metabol.by cytochrome P-450 system.& for 4-5   ERAXIS, Pfizer [P/S] &
   See Section 11.3             days  aft.discont.  fluconazole,  monit.pts.develop.abnorm.liv.funct.
                                for more ser.hepat.injur., discont.if clinic.S&S of liv. dis./ bullous   Anidulafungin
                                                              Indications: Invas.candidias.incl.candidaem.in adults.
   DIFLUCAN, Pfizer [P/S]       les./erythema multiforme develop, assess risk benefit ratio of   (S4) POWD.FOR SOL.FOR INFUS, 44/20.1.7/0355
   Fluconazole.                 contin.admin.in pts.with signific. rise in liv.enzym., monit.multiple   720415-001: 100 mg, 1xsngl.use vial, R2 564,83
   Indications:  Ac/recurr.vag.candidiasis  &  prophylax.  to  reduc.  dos.ther. in ren.impairm., prodysrhythm.condits.incl.QT interv.   Dosage: Reconstit.with water for inj.& dil.only with 0,9% NaCl or 5%
   recurr.incid of vag.candidias., candidial balanitis, dermatomycosis   prolongat./torsade de pointes., monit.pts. on long-term treatm.   gluc.for infus. Max.infus. rate not exceed.1,1 mg/min. Treatm.durat.
   incl.tinea pedis, tinea corporis, tinea cruris, tinea unguium   with fluconazole & prednisone for adren.insuff.when fluconazole is   depend. on pt.clinic.respons.& gen.at least x14 days aft. last posit.cult.
   (onychomycosis) & derm.candida infects.  discont., Caps: lact intol. Powd: pts with heredit. fruct. intol./gluc.-  Sngl.load.dos: 200 mg on day 1 follow.by 100 mg dly.thereaft.
   (S4) CAPS, [P/S] V/20.2.2/340.  galact. malabsorpt./sucrose-isomaltase.defic.  Contraindications: Echinocandin class. hypersens., pregn.& lac-
   786373-008: 150 mg, 1, R120,76  Drug interactions: Prolongs prothromb.time in warfarin ther., pro-  tat., pts.und.18 yrs.
   786373-091: 150 mg, 4, R483,05  longs serum half-life of oral sulphonylureas, incr.midazolam conc.
   Dosage: Vag.candidiasis: 150 mg as sngl.oral dose.  partic.aft. oral admin., cyclospor.conc.grad.incr.aft.ren. transplan-  Side effects: Fungaem., candidias., pseudomembran. colit., oral
                                                              candidias., thrombocytopen./-cythaem., coagulopathy, hyper-/hy-
   Reduc.incid.of recurr.vag.candidias: 150  mg once monthly   tat., multiple hydrochlorothiazide dos. incr.fluconazole plasma conc.,
   indiv.durat.which range from 4-12 mnths.  phenytoin/rifabutin /tacrolimus plasma conc.incr., theophyll.clear.   pokalaem., hypomagnesaem., hyperglycaem., hypercalcaem., hyper-
                                                              natraem., convuls., headache, eye pain, vis.disturbs., blurr.vis., atrial
   Candida balanitis: 150 mg as sngl.oral dos.  decr., rifampicin reduc.fluconazole half life & AUC, incr. zidovudine
   Derm.infects.eg.tinea pedis, corporis, cruris and candida   plasma conc., incr.terfenadine conc. follow.high dos.fluconazole as-  fibrillat., sinus dysrhythm., ventric.extrasystoles, bundle branch block
   infects: 150 mg once wkly.x2-4 wks. but up to 6 wks.for tinea pedis.  soc.with card. dysrhythm., card.events incl.torsades de pointes/ QT   right, flush., thrombos., hypertens., hot flush., GI disturbs., abnorm.LFT,
   Tinea unguium: 150  mg once wkly.x3-12 mnths until nail   interv,prolongat.with cisapride/astemizole/ erythromycin/ pimozide/   cholestas., hepat.enzyme incr., transaminase.incr., skin reacts. incl.
   completely replac.           quinidine, plasma lev.of concom. cisapride incr., astemizole clear.decr.,   rash/urticar./prurit., dyspn., back pain, infus. site pain/reacts., prolong.
   (S4) CAPS, [P/S] V/20.2.2/339, 28/20.2.2/151.  quinidine/pimozide clear.inhib., incr.plasma conc. of meds.metabol.   ECG QT, abnorm.ECG, bld.dyscras., neutropen., leucopen., anaem, hy-
   Indications:  Cryptococ.meningit.in mentally alert pts.without   by cytochrome P-450 system.  peruricaem., hypocalcaem./-natraem./-albuminaem./-phosphataem.,
   localis.neurolog.signs & as follow up ther. aft. Amphoterecin B ther,   DIFLUZOLE 150, Cipla Medpro [P/S]  anx., delir., confus. audit.hallucinat., dizzin., paraesthes., centr. pon-
   maint.ther.to prevent cryptococ.dis.relapse in AIDS pts., system.   Fluconazole  tine myelinolys., dysgeus., Guillain-Barre syndr., trem., alt.vis.depth
   candidias., oropharyngeal & oesophag. candidias., fung.infect.  Indications: Ac/recurr.vag.candidiasis & prophylax. to reduc.recurr.  percept., unilat.deafn., phlebit., superfic.thrombophlebit., hypotens.,
   prophylax.in pts. with malign. predispos. to such infects.due to   incid of vag.candidias., candidial balanitis, dermatomycos.incl. tinea   lymphangit., dyspeps.,dry mouth, oesophag.ulc., hepat. necros., an-
   cytotox.chemo & radiother.   corporis, tinea cruris, tinea pedis, tinea unguium (onychomycosis) &   gioed., hyperhidros., myalg., monoarthrit., ren.fail., haematur., pyrex.,
   786365-102: 50 mg, 14, R559,30                             chills, periph. oed, incr.bld.creatine phosphokin./bld. lactate dehydro-
   820539-007: 200 mg, 28, R3 021,45  derm.candida infects.   gen., decr.lymphocyte count.
                                (S4) CAPS, 38/20.2.2/0102
   (S4) SUSP, [P/S] 30/20.2.2/0150, 0151.                     Warnings and special precautions: Monit.for worsen.hepat.
   883686-002: 50 mg/5 ml 35 ml, R260,80  703635-001: 150 mg, 1, R30,92  funct. & eval.risk:benefit if abnorm. LFT develop, hepat.abnormalit.
                                Dosage: Dos.& durat.bas.on site of infect.& indiv. respons.to ther.
   836443-004: 200 mg/5 ml 35 ml, R809,12                     occur.with ser. underly.medic. condits.& multiple concom.meds., ter-
   (S4) INFUS, [P/S] Z/20.2.2/272. 2 mg/ml.  Cont.ther.until clinic.paramet.& lab. tests indic.act.infect.subsid.  atogen.& excret.in breastmilk in anim.stud., do not mix./co-admin.
                                Adults:
   799130-028: 100 ml, R253,16                                with other meds./electrol.
   Dosage: Cont.ther.requir.multipl.dos.treatm.until lab.tests & clinic.  Vag.candidiasis: 150 mg as sngl.oral dose.  Interactions: Ciclosporin incr.AUC., monit.for worsen. hepat. funct.
   paramet.indic.act.infect.subsid. Maint.ther.usually reqd.in AIDS pts.  Reduc.incid.of recurr.vag.candidias: 150 mg as sngl.dos.once   & eval.risk:benefit if abnorm. LFT develop
   with cryptococc. meningit/recurr.oropharyng.candidias. Infusion   mnthly. Indiv.durat.which range from 4-12 mnths.  See also MDR page 610.
   may be infus.at max.rate of 200 mg/hr. with compat.admin.fluid.   Candida balanitis: 150 mg as sngl.oral dos.  EXOMAX, (Ascendis) Dezzo [P/S]
   Mix.with any other drugs not recomm.  Derm.infects.eg.tinea pedis/corporis/cruris and candida in-
   Adults:                      fects: 150 mg once wkly.x2-4 wks. but up to 6 wks.for tinea pedis.  Fluconazole
                                                              Indications: Adults & childr: Cryptococ. meningit. in ment.alert pts.
   Cryptococ.meningit: 400 mg on 1st day, then 200 mg dly x6-8   Tinea unguium: 150 mg once wkly.x3-12 mnths until nail com-
   wks, may be incr.to 400 mg dly. depend.on clinic.respon.  pletely replac.  without local. neurologic. signs & follow-up ther.aft. amphotericin B
   Prevent.of cryptococ.meningit.relapse in AIDS pts: Aft.full   (S4) CAPS, 38/20.2.2/0103  ther., maint.ther.to prev.cryptococ. dis. relapse in AIDS pts., system.
   course of prim.therapy 100-200 mg dly.  Indications: Adults & childr: Cryptococ. meningit. in ment.alert   candidias., oropharyng. & oesophag. candidias., fung.infect. prophy-
   System.candidias: 1st day 400  mg, then 200  mg dly. Durat.  pts.without local. neurologic. signs & follow-up ther.aft. ampho-  lax. in pts.receiv.cytotox.chemo and/or radiother.
   depend.on clinic.respons.may be incr.to 400  mg dly depend.on   tericin B ther., maint.ther.to prev.cryptococ. dis.relapse in AIDS pts.,   Adults: Also ac/recurr.vag.candidiasis & as prophylax. to reduc.
   clinic.respons.              oropharyng.& oesophag. candidias., system.candidias., fung.infect.   recurr.incid., candidial balanitis, dermatomycos. incl.tinea pedis,
   Oropharyngeal candidias: Recomm.dos: 50-100 mg once dly.x7-  prophylax. in pts.receiv.chemo and/or radiother.  tinea corporis, tinea cruris, tinea unguium (onychomycosis) & derm.
   14 days/long.in sev. immunocompris. pts. To prev.relapse in AIDS   703637-001: 200 mg, 30, R350,00  candida infects.
   pts. aft. full course prim.ther.admin.150 mg once wkly.  Cryptococc.meningit: Adults: Init: 400 mg on day one then 200-  (S4) IV INFUS, A40/20.2.2/0115. 2 mg/ml.
                   st
   Oesophag.candidiasis: 200 mg on 1  day follow. by 100-200 mg   400 mg dly.for upto 8 wks. Childr.over 4 wks: 6 mg/kg/day.   714989-001: 1 x 100 ml, R53,06
   once dly.with dos.of up to 400 mg dly accord.to pt.respons. Treat for   Maint.ther.to prev.cryptococc.meningit.in AIDS pts: Adults:   Dosage: Cont.ther.requir.multipl.dos.treatm.until lab. tests & clinic.
   min.3 wks.& x2 wks.aft.sympt.resolut.  100-200 mg/day      paramet.indic.act.infect.subsid. Maint. ther.usually reqd.in AIDS pts.
   Candidias.prophylax: 50-400 mg once dly.bas. on risk profile. Pts.  Syst.candidias: Adults: Init.400 mg on day one follow.by 200 mg   with cryptococc. meningit/recurr.oropharyng.candidias. Infts. und.2
   at high risk of system.infect. i.e. those anticipat.to have profound/  dly.incr.to 400 mg dly.depend.on clinic.respon. Childr.over 4 wks:   wks.to receiv.childr.dos.but only given once every 72 hrs. Infts.2-4
   prolong. neutropen. have receiv.400 mg once dly. Commenc. ther.  6-12 mg/kg/day depend.on sever. Durat.bas.on clinic.& myco-  wks.to receiv.childr. dos. every 48 hrs. Max.adult dly.dos.of 400 mg
   sev.days bef.anticipat.neutropen & contin.x7 days aft.neutrophil   logic. respons.  not to be exceed.in childr.
   count rises above 1000 cells per mm 3  Oropharyngeal candidias: Adults: 50-100 mg dly.x7-14 days.   Infusion may be infus.at max.rate of 200 mg/hr. with compat.admin.
   Children:                    Sev.immunocomprom.may req.long. treatm. To prev.relapse in AIDS   fluid. Mix.with any other drugs not recomm.
   Do not exceed.max.adult dly dos. Admin.as sngl. dly.dos.  pts.admin.150 mg once wkly. Childr.over 4 wks: Init.6 mg/kg then   Cryptococ.meningit: Adults: 400 mg on 1st day, then 200-400 mg
                     st
   Oropharyngeal candidias: 6 mg/kg on 1  day follow. by 3 mg/kg   3 mg/kg once dly.for at least 2 wks.  dly depend.on clinic.respon.but usual.8 wks.follow.amphotericin B
   once dly.x2 wks.at least to decr. likelihood of relapse.  Oesophageal candidias: Adults: Init.200 mg on day one, then   ther & 10 wks. with monother. Childr.over 4 wks: 6–12 mg/kg/
   Oesophag.candidias: 6 mg/kg on 1  day follow. by 3 mg/kg once   100-200 mg dly. Incr. to 400 mg dly.if no respons.aft.14 days. Treat   day depend.on severit.
                  st
   dly.with dos.of up to 12 mg/kg/ day accord.to pt.respons. Treat for   for 3 wks.& add 2 wks. Childr.over 4 wks: Init.6 mg/kg on day one   Maint.ther.to prevent.cryptococ.meningit. relapse in AIDS pts:
   min.3 wks.& x2 wks.aft.sympt.resolut.  then 3 mg/kg dly. Incr.to 12 mg/kg/day if not respond. Treat for 3   Adults: 100-200 mg dly.
                                                                                 st
   System.candidias.&  cryptococc.infect:  6-12  mg  /kg/day   wks.& add 2 wks.  System.candidias: Adults: Init.400 mg on 1  day, then 200 mg dly.
   depend.on severity.          Fung.infect.prophylax.in pts.receiv.cytotox. chemother./ra-  Dos.may be incr.to 400 mg dly. depend.on clinic.respons. Childr.over
   Fung.infect.prophylax.in immunocomprom. pts. at risk as a   diat: Adults: 50-400 mg dly. Init. sev.days bef.expect.neutropen. &   4 wks: 6–12 mg/kg/day depend.on severit.
   consequenc.of neutropen. follow.cytotox.chemo/radiother:   cont.x7 days aft.neutrophil count above 1 000 cells/m Childr. over   Oropharyngeal candidias: Adults: 50-100 mg once dly.x7-14
                                                      3.
   3-12 mg/kg dly.depend.on extent & durat.of induc.neutropen.  4 wks: 3-12 mg/kg/day.  days/long.in sev.immunocompris. pts. To prev.relapse in AIDS pts.ad-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page288.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page284.html">284</a>&nbsp;&nbsp;&nbsp;<a href="page285.html">285</a>&nbsp;&nbsp;&nbsp;<a href="page286.html">286</a>&nbsp;&nbsp;&nbsp;<a href="page287.html">287</a>&nbsp;&nbsp;&nbsp;<a href="page288.html">288</a>&nbsp;&nbsp;&nbsp;<a href="page289.html">289</a>&nbsp;&nbsp;&nbsp;<a href="page290.html">290</a>&nbsp;&nbsp;&nbsp;<a href="page291.html">291</a>&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>
             </td>
             <td width="35%"><a href="page290.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page290.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
